Examining the rejection of Lee’s Saxagliptin CL application
Last July, an anonymous tip-off led us to Lee Pharma’s application for a Compulsory License against AstraZeneca’s Saxagliptin patent (IN206543). In that post, Swaraj and I covered the merits of Lee’s application extensively, before concluding that it was unlikely to succeed. In August, the IPO issued a prima facie finding rejecting the application under Rule 97(1) of the Patent Rules, 2003. Lee’s counsel requested a hearing, and were granted one on 15 December 2015 along with supplementary submissions on 29 […]
Examining the rejection of Lee’s Saxagliptin CL application Read More »